Innoviva Cash Flow from Operating Activities 2010-2024 | INVA
Innoviva cash flow from operating activities from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
Innoviva Annual Cash Flow Ops
(Millions of US $) |
| 2024 |
$189 |
| 2023 |
$141 |
| 2022 |
$202 |
| 2021 |
$364 |
| 2020 |
$313 |
| 2019 |
$257 |
| 2018 |
$224 |
| 2017 |
$142 |
| 2016 |
$61 |
| 2015 |
$10 |
| 2014 |
$-131 |
| 2013 |
$-130 |
| 2012 |
$-128 |
| 2011 |
$-88 |
| 2010 |
$-75 |
| 2009 |
$-58 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.132B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
